Caxton Associates LLP Takes Position in 10x Genomics $TXG

Key Points

• Caxton Associates LLP has acquired a total of 346,794 shares of 10x Genomics, valued at approximately $3,028,000, representing a 0.28% ownership stake in the company.
• The company reported a quarterly EPS of $0.28, surpassing analysts' expectations, along with a revenue of $172.91 million, reflecting a 12.9% year-over-year increase.
• Institutional ownership of 10x Genomics stands at 84.68%, with multiple large investors increasing their positions during the first quarter.

Caxton Associates LLP acquired a new position in shares of 10x Genomics (NASDAQ:TXG - Free Report) in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 346,794 shares of the company's stock, valued at approximately $3,028,000. Caxton Associates LLP owned 0.28% of 10x Genomics as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of the stock. ARK Investment Management LLC grew its holdings in 10x Genomics by 7.5% in the first quarter. ARK Investment Management LLC now owns 12,845,713 shares of the company's stock worth $112,143,000 after purchasing an additional 901,656 shares during the period. Vanguard Group Inc. grew its holdings in 10x Genomics by 1.7% in the first quarter. Vanguard Group Inc. now owns 11,118,086 shares of the company's stock worth $97,061,000 after purchasing an additional 184,537 shares during the period. Millennium Management LLC grew its holdings in 10x Genomics by 434.5% in the first quarter. Millennium Management LLC now owns 5,377,492 shares of the company's stock worth $46,946,000 after purchasing an additional 4,371,327 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in 10x Genomics by 10.1% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,116,573 shares of the company's stock worth $30,394,000 after purchasing an additional 193,588 shares during the period. Finally, Voloridge Investment Management LLC grew its holdings in 10x Genomics by 12.1% in the fourth quarter. Voloridge Investment Management LLC now owns 1,585,965 shares of the company's stock worth $22,774,000 after purchasing an additional 171,161 shares during the period. 84.68% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, insider Benjamin J. Hindson sold 7,486 shares of the firm's stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $13.79, for a total transaction of $103,231.94. Following the completion of the sale, the insider owned 440,888 shares in the company, valued at approximately $6,079,845.52. This trade represents a 1.67% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Serge Saxonov sold 9,348 shares of the firm's stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $13.79, for a total transaction of $128,908.92. Following the sale, the chief executive officer owned 945,892 shares of the company's stock, valued at $13,043,850.68. This trade represents a 0.98% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 39,149 shares of company stock worth $539,865. Insiders own 10.03% of the company's stock.

10x Genomics Price Performance

TXG opened at $13.96 on Monday. The company's 50-day moving average is $13.15 and its 200 day moving average is $10.74. 10x Genomics has a fifty-two week low of $6.78 and a fifty-two week high of $24.38. The firm has a market capitalization of $1.74 billion, a P/E ratio of -19.94 and a beta of 2.00.

10x Genomics (NASDAQ:TXG - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported $0.28 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.35) by $0.63. 10x Genomics had a negative net margin of 13.13% and a negative return on equity of 12.88%. The business had revenue of $172.91 million during the quarter, compared to the consensus estimate of $139.36 million. During the same quarter last year, the company posted ($0.32) earnings per share. The firm's quarterly revenue was up 12.9% compared to the same quarter last year. 10x Genomics has set its Q3 2025 guidance at EPS. On average, equities research analysts expect that 10x Genomics will post -1.43 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts have commented on TXG shares. Deutsche Bank Aktiengesellschaft set a $14.00 price target on shares of 10x Genomics and gave the stock a "hold" rating in a report on Friday, August 8th. The Goldman Sachs Group dropped their price objective on shares of 10x Genomics from $7.50 to $6.50 and set a "sell" rating on the stock in a research note on Monday, May 12th. Morgan Stanley dropped their price objective on shares of 10x Genomics from $18.00 to $17.00 and set an "overweight" rating on the stock in a research note on Tuesday, August 12th. Canaccord Genuity Group set a $16.00 price objective on shares of 10x Genomics in a research note on Monday, August 11th. Finally, Stephens reaffirmed an "overweight" rating and issued a $14.00 price objective on shares of 10x Genomics in a research note on Thursday, May 15th. Six investment analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, 10x Genomics presently has an average rating of "Hold" and a consensus target price of $13.54.

10x Genomics Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.

Want to see what other hedge funds are holding TXG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for 10x Genomics (NASDAQ:TXG - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.